|
|
|
|
LEADER |
02740nam a2200289Ia 4500 |
001 |
10.1186-s12871-022-01654-0 |
008 |
220510s2022 CNT 000 0 und d |
020 |
|
|
|a 14712253 (ISSN)
|
245 |
1 |
0 |
|a Effects of adding low-dose ketamine to etomidate on serum cortisol levels in critically ill cardiac patients: a randomized clinical trial
|
260 |
|
0 |
|b BioMed Central Ltd
|c 2022
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1186/s12871-022-01654-0
|
520 |
3 |
|
|a Background: Etomidate was associated with an inhibition of adrenal steroid synthesis. This study aimed to evaluate the effects of adding low-dose ketamine to etomidate to minimize the decrease in serum cortisol level in critically ill cardiac patients. Methods: Sixty adult cardiac patients, ≥ 18 years, who underwent upper endoscopy and Colonoscopy to manage acute anemia in the cardiac intensive care units were enrolled. Patients were randomly divided into two groups: (group (E): n = 30) received etomidate 0.2 mg/kg IV followed by etomidate 0.05 mg/kg IV, and (group (KE): n = 30) received ketamine 0.5 mg/kg IV, then etomidate 0.1 mg/kg IV, followed by etomidate 0.05 mg/kg IV. The primary outcome was Serum cortisol level at 6 h after the procedure. Results: The mean postoperative cortisol level was significantly lower in group E (295.60 ± 49.218 nmol/L) versus group KE (461.00 ± 67.946 nmol/L), with 95% CI = 351.94 to 404.66; p = 0.000. In addition, the estimated serum cortisol reduction level was also significant between groups; In group E, the estimated cortisol level decreased nearly 53% from 632.40 ± 35.066 nmol/L to 295.60 ± 49.218 nmol/L 6 hours postoperative. While in group KE, the estimated cortisol level decreased only 27% from 639.13 ± 43.035 nmol/L to 461.00 ± 67.946 nmol/L. Conclusions: Single-dose ketamine (0.5 mg/kg) was helpful to decrease the total dose of etomidate and hence decreased the percentage of serum cortisol level in such critically ill patients with preservation of patient satisfaction. Trial Registration: This study is registered on ClinicalTrials.gov (NCT04857450; principal investigator: Mostafa Mohammed Elsaid Elhamamsy; registration date: 23/04/ 2021). © 2022, The Author(s).
|
650 |
0 |
4 |
|a Acute anemia
|
650 |
0 |
4 |
|a Critically ill cardiac patients
|
650 |
0 |
4 |
|a Etomidate
|
650 |
0 |
4 |
|a Ketamine
|
650 |
0 |
4 |
|a Serum Cortisol
|
650 |
0 |
4 |
|a Upper endoscopy and Colonoscopy
|
700 |
1 |
|
|a Abdelhady, M.A.
|e author
|
700 |
1 |
|
|a Aldemerdash, A.M.
|e author
|
700 |
1 |
|
|a AlSaud, S.A.
|e author
|
700 |
1 |
|
|a Boules, M.L.
|e author
|
700 |
1 |
|
|a Elhamamsy, M.M.
|e author
|
700 |
1 |
|
|a Ezz, G.F.M.
|e author
|
700 |
1 |
|
|a Hamed, M.A.
|e author
|
700 |
1 |
|
|a Zahran, F.B.
|e author
|
773 |
|
|
|t BMC Anesthesiology
|